DEXAMETHASONE PALMITATE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C38H59FO6
Molecular Weight	630.8699
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C

InChI

InChIKey=WDPYZTKOEFDTCU-WDJQFAPHSA-N

InChI=1S/C38H59FO6/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-34(43)45-26-33(42)38(44)27(2)23-31-30-20-19-28-24-29(40)21-22-35(28,3)37(30,39)32(41)25-36(31,38)4/h21-22,24,27,30-32,41,44H,5-20,23,25-26H2,1-4H3/t27-,30+,31+,32+,35+,36+,37+,38+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C38H59FO6
Molecular Weight	630.8699
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	8 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://books.google.ru/books?id=pdrrEiTBVPAC&pg=PA33&lpg=PA33&dq=Limethason+japan&source=bl&ots=vObXQgrmRf&sig=CPRGB1n2y5XRMryGLq9ANc1KZiA&hl=en&sa=X&ved=0ahUKEwiSodCnjrTPAhXCBiwKHbyhDeoQ6AEIKTAD#v=onepage&q=Limethason%20japan&f=false Retrieved from Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs By Rainer H. Müller, Simon Benita, Bernhard H. L. Böhm, p.33
Curator's Comment: Description was created based on several sources, including http://www.ndrugs.com/?s=limethason

Dexamethasone palmitate (a derivative of Dexamethasone), anti-inflammatory, antirheumatic, glucocorticoid receptor agonist, is reported as an ingredient of Limethason in Japan and Lipotalon in Germany. Limethason (Dexamethasone palmitate) inhibits the function of leukocytes and tissue macrophages. It restricts the migration of leukocytes in the area of inflammation. Limethason (Dexamethasone palmitate) decreases capillary permeability caused by histamine release. It inhibits the activity of fibroblasts and collagen formation. Limethason inhibits the activity of phospholipase A2, which leads to suppression of the synthesis of prostaglandins and leukotrienes. Limethason (Dexamethasone palmitate) is indicated for rheumatoid arthritis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Macrophage viability and migration 1 Target ID: Macrophage viability and migration Sources: https://www.ncbi.nlm.nih.gov/pubmed/24806147	Inhibitor 8504
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D01615	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Rheumatoid arthritis 320 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24754272	Primary		Approved 8583	Limethason Approved Use Indications: rheumatoid arthritis Launch Date 1988

PubMed

Title	Date	PubMed
Acute Treatment of Facet Syndrome by CT-Guided Injection of Dexamethasone-21-Palmitate Alone and in Combination with Mepivacaine.	2004	17523717

Patents

Sample Use Guides

In Vivo Use Guide

0.25mg/kg, intravenous

Route of Administration: Intravenous

In Vitro Use Guide

DEXAMETHASONE PALMITATE decreased the viability of RAW 264.7 cells by 75% at a concentration of 10 uM

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:07:25 GMT 2025` Edited by `admin` on `Mon Mar 31 21:07:25 GMT 2025`
Record UNII	601XWN7060
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DEXAMETHASONE PALMITATE

Common Name

English

NOVA63035

Preferred Name

English

9-FLUORO-11,17-DIHYDROXY-16-METHYL-21-((1- OXOHEXADECYL)OXY)PREGNA-1,4-DIENE-3,20-DIONE (11.BETA.,16.ALPHA.)-

Common Name

English

DEXAMETHASONE PALMITATE [JAN]

Common Name

English

DEXAMETHASONE 21-PALMITATE

Common Name

English

NOVA-63035

Common Name

English

Dexamethasone palmitate [WHO-DD]

Common Name

English

Code System Code Type Description

DRUG CENTRAL

828